Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples

Hye young Wang, Sunghyun Kim, Sangjung Park, Seungil Kim, Dongju Jung, Kwang Hwa Park, Hyeyoung Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Breast cancer patients who have a positive result for HER2 overexpression are commonly treated with Herceptin, a HER2-targeted therapy. In the present study, the BrightGen HER2 RT-qDx (Syantra, Calgary, Canada), which is based on a one-tube nested RT-qPCR method that detects HER2 mRNA overexpression, was clinically evaluated in a total of 237 formalin-fixed paraffin-embedded (FFPE) tissue samples from breast cancer patients. Among the 38 HER2 positive samples, which were determined via IHC/FISH methods, 13 samples out of 16 (81.3%) that were IHC2. +/FISH. + and 22 samples out of 22 (100%) that were IHC3. + have been decided positive for HER2 expression via the RT-qPCR method. The true positivity and false positivity results for the RT-qPCR were 92% (35/38) and 2% (1/65), respectively. The concordance between RT-qPCR and IHC results and RT-qPCR and IHC/FISH was 87.2% and 92.1%, respectively. Conclusively, the BrightGen HER2 RT-qDx may be a reliable and convenient method that can supplement traditional IHC and FISH methods for efficient use of trastuzumab.

Original languageEnglish
Pages (from-to)368-374
Number of pages7
JournalExperimental and Molecular Pathology
Volume97
Issue number3
DOIs
Publication statusPublished - 2014 Sep 16

Fingerprint

Assays
Tissue
Breast Neoplasms
Polymerase Chain Reaction
Messenger RNA
Paraffin
Formaldehyde
Therapeutics
Canada
Trastuzumab

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Wang, Hye young ; Kim, Sunghyun ; Park, Sangjung ; Kim, Seungil ; Jung, Dongju ; Park, Kwang Hwa ; Lee, Hyeyoung. / Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples. In: Experimental and Molecular Pathology. 2014 ; Vol. 97, No. 3. pp. 368-374.
@article{ddad19325c93449fb5eb73f9e1d2fcfd,
title = "Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples",
abstract = "Breast cancer patients who have a positive result for HER2 overexpression are commonly treated with Herceptin, a HER2-targeted therapy. In the present study, the BrightGen HER2 RT-qDx (Syantra, Calgary, Canada), which is based on a one-tube nested RT-qPCR method that detects HER2 mRNA overexpression, was clinically evaluated in a total of 237 formalin-fixed paraffin-embedded (FFPE) tissue samples from breast cancer patients. Among the 38 HER2 positive samples, which were determined via IHC/FISH methods, 13 samples out of 16 (81.3{\%}) that were IHC2. +/FISH. + and 22 samples out of 22 (100{\%}) that were IHC3. + have been decided positive for HER2 expression via the RT-qPCR method. The true positivity and false positivity results for the RT-qPCR were 92{\%} (35/38) and 2{\%} (1/65), respectively. The concordance between RT-qPCR and IHC results and RT-qPCR and IHC/FISH was 87.2{\%} and 92.1{\%}, respectively. Conclusively, the BrightGen HER2 RT-qDx may be a reliable and convenient method that can supplement traditional IHC and FISH methods for efficient use of trastuzumab.",
author = "Wang, {Hye young} and Sunghyun Kim and Sangjung Park and Seungil Kim and Dongju Jung and Park, {Kwang Hwa} and Hyeyoung Lee",
year = "2014",
month = "9",
day = "16",
doi = "10.1016/j.yexmp.2014.09.011",
language = "English",
volume = "97",
pages = "368--374",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "3",

}

Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples. / Wang, Hye young; Kim, Sunghyun; Park, Sangjung; Kim, Seungil; Jung, Dongju; Park, Kwang Hwa; Lee, Hyeyoung.

In: Experimental and Molecular Pathology, Vol. 97, No. 3, 16.09.2014, p. 368-374.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples

AU - Wang, Hye young

AU - Kim, Sunghyun

AU - Park, Sangjung

AU - Kim, Seungil

AU - Jung, Dongju

AU - Park, Kwang Hwa

AU - Lee, Hyeyoung

PY - 2014/9/16

Y1 - 2014/9/16

N2 - Breast cancer patients who have a positive result for HER2 overexpression are commonly treated with Herceptin, a HER2-targeted therapy. In the present study, the BrightGen HER2 RT-qDx (Syantra, Calgary, Canada), which is based on a one-tube nested RT-qPCR method that detects HER2 mRNA overexpression, was clinically evaluated in a total of 237 formalin-fixed paraffin-embedded (FFPE) tissue samples from breast cancer patients. Among the 38 HER2 positive samples, which were determined via IHC/FISH methods, 13 samples out of 16 (81.3%) that were IHC2. +/FISH. + and 22 samples out of 22 (100%) that were IHC3. + have been decided positive for HER2 expression via the RT-qPCR method. The true positivity and false positivity results for the RT-qPCR were 92% (35/38) and 2% (1/65), respectively. The concordance between RT-qPCR and IHC results and RT-qPCR and IHC/FISH was 87.2% and 92.1%, respectively. Conclusively, the BrightGen HER2 RT-qDx may be a reliable and convenient method that can supplement traditional IHC and FISH methods for efficient use of trastuzumab.

AB - Breast cancer patients who have a positive result for HER2 overexpression are commonly treated with Herceptin, a HER2-targeted therapy. In the present study, the BrightGen HER2 RT-qDx (Syantra, Calgary, Canada), which is based on a one-tube nested RT-qPCR method that detects HER2 mRNA overexpression, was clinically evaluated in a total of 237 formalin-fixed paraffin-embedded (FFPE) tissue samples from breast cancer patients. Among the 38 HER2 positive samples, which were determined via IHC/FISH methods, 13 samples out of 16 (81.3%) that were IHC2. +/FISH. + and 22 samples out of 22 (100%) that were IHC3. + have been decided positive for HER2 expression via the RT-qPCR method. The true positivity and false positivity results for the RT-qPCR were 92% (35/38) and 2% (1/65), respectively. The concordance between RT-qPCR and IHC results and RT-qPCR and IHC/FISH was 87.2% and 92.1%, respectively. Conclusively, the BrightGen HER2 RT-qDx may be a reliable and convenient method that can supplement traditional IHC and FISH methods for efficient use of trastuzumab.

UR - http://www.scopus.com/inward/record.url?scp=84907542997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907542997&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2014.09.011

DO - 10.1016/j.yexmp.2014.09.011

M3 - Article

VL - 97

SP - 368

EP - 374

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 3

ER -